公开(公告)号：USRE49700E1

公开(公告)日：2023-10-17

申请号：US17183286

申请日：2021-02-23

Applicant: Bristol-Myers Squibb Company

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof,

wherein R1 is:





each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US10730868B2

公开(公告)日：2020-08-04

申请号：US16317218

申请日：2017-07-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qinghong Fu ,  Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D417/14 ,  C07D417/10 ,  C07D513/04 ,  C07D417/04

Abstract: Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20200123160A1

公开(公告)日：2020-04-23

申请号：US16538917

申请日：2019-08-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  UNIVERSITÉ DE MONTRÉAL

Inventor： Jacques Banville ,  Roger Remillard ,  Edward H. Ruediger ,  Daniel H. Deon ,  Marc Gagnon ,  Laurence Dube ,  Julia Guy ,  Eldon Scott Priestley ,  Shoshana L. Posy ,  Brad D. Maxwell ,  Pancras C. Wong ,  R. Michael Lawrence ,  Michael M. Miller

IPC: C07D487/04 ,  C07B59/00 ,  A61K51/04 ,  A61K31/55 ,  A61K31/5386 ,  A61K31/435 ,  A61K31/553 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/5025 ,  A61K31/497 ,  A61K31/496 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/433 ,  C07D513/04 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

公开(公告)号：US20190315774A1

公开(公告)日：2019-10-17

申请号：US16317258

申请日：2017-07-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： XIAOJUN Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Wen Jiang ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D519/00 ,  A61P7/02 ,  C07D515/14

Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20150148313A1

公开(公告)日：2015-05-28

申请号：US14405507

申请日：2013-06-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiaojun Zhang ,  Peter Glunz ,  Eldon Scott Priestley ,  James A. Johnson ,  Nicholas Ronald Wurtz ,  Vladimir Ladziata

IPC: C07D413/12 ,  C07F9/6558 ,  C07D413/14 ,  C07D401/12 ,  C07D417/14

CPC classification number: C07D413/12 ,  C07D273/02 ,  C07D401/12 ,  C07D413/14 ,  C07D417/14 ,  C07F9/65583

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是可用作药物的因子VIIa抑制剂。

公开(公告)号：US20240309019A1

公开(公告)日：2024-09-19

申请号：US18530405

申请日：2023-12-06

Applicant: Bristol-Myers Squibb Company

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Wen Jiang ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D519/00 ,  A61P7/02 ,  C07D515/14

CPC classification number: C07D519/00 ,  A61P7/02 ,  C07D515/14

Abstract: Disclosed are compounds of Formula (I) to (VIII):




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20230124468A1

公开(公告)日：2023-04-20

申请号：US17960199

申请日：2022-10-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20210188877A1

公开(公告)日：2021-06-24

申请号：US17142288

申请日：2021-01-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Wen Jiang ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D519/00 ,  A61P7/02 ,  C07D515/14

Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US10723723B2

公开(公告)日：2020-07-28

申请号：US16344823

申请日：2017-11-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prashantha Gunaga ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Manoranjan Panda ,  Navnath Dnyanoba Yadav ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P13/02 ,  A61P9/00 ,  A61P9/12 ,  A61P9/04 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US10047103B2

公开(公告)日：2018-08-14

申请号：US15593534

申请日：2017-05-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  Universite De Montreal

Inventor： Jacques Banville ,  Roger Remillard ,  Edward H. Ruediger ,  Daniel H. Deon ,  Marc Gagnon ,  Laurence Dube ,  Julia Guy ,  Eldon Scott Priestley ,  Shoshana L. Posy ,  Brad D. Maxwell ,  Pancras C. Wong ,  R. Michael Lawrence ,  Michael M. Miller

IPC: C07D513/04 ,  C07D487/04 ,  C07D519/00 ,  A61K45/06 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/553 ,  A61K31/435 ,  A61K31/5386 ,  A61K31/55 ,  A61K51/04 ,  C07B59/00

CPC classification number: C07D513/04 ,  A61K31/433 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61K45/06 ,  A61K51/0453 ,  C07B59/002 ,  C07B2200/05 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.